EBV Mosaic EBNA1 protein [GST] (DAG1577)

EBV Mosaic EBNA1 protein [GST], recombinant protein from E. coli

Product Overview
Recombinant EBV NA protein fused with GST tag was expressed in E. coli and purified by proprietary chromatographic technique.
Nature
Recombinant
Tag/Conjugate
GST
Procedure
None
Purity
> 95% pure as determined by 10% PAGE (coomassie staining).
Buffer
50mM Tris-HCl pH 8, 10mM glutation, 60mM NaCl and 0.5% sarcosyl.
Preservative
None
Storage
2-8°C short term, -20°C long term
Introduction
The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalovirus. On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions. A very limited, distinct set of viral proteins are produced during latent cycle infection. These include Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane proteins (LMP)-1, LMP-2A and LMP-2B and the Epstein-Barr encoded RNAs (EBERs).
Antigen Description
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.
Keywords
EBV; Epstein-Barr virus; human herpesvirus 4; HHV-4; EBNA-1; Epstein-Barr Virus Nuclear Antigen; EBV Nuclear Antigen protein; human herpesvirus 4 Nuclear Antigen; HHV-4 Nuclear Antigen; Herpesviridae; Gammaherpesvirinae; Lymphocryptovirus; Human herpesvir

Citations


Have you cited DAG1577 in a publication? Let us know and earn a reward for your research.

Related Products


EBV [His] (DAG1578)
EBV [GST] (DAG1580)
EBV [GST] (DAG1581)
EBV [His] (DAG1584)

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Human herpesvirus-8-positive primary effusion lymphoma in HIV-negative patients: Single institution case series with a multidisciplinary characterization

CANCER CYTOPATHOLOGY

Authors: Rossi, Giovanni; Cozzi, Ilaria; Della Starza, Irene; De Novi, Lucia Anna; De Propris, Maria Stefania; Gaeta, Aurelia; Petrucci, Luigi; Pulsoni, Alessandro; Pulvirenti, Federica; Ascoli, Valeria

BACKGROUND Primary effusion lymphoma (PEL) is a very rare non-Hodgkin lymphoma caused by human herpesvirus-8 (HHV8) that grows in liquid phase within body cavities. The diagnosis of PEL is based on cytology but requires confirmatory ancillary tests. PEL occurs mainly in association with HIV infection. This study describes 9 cases of PEL in HIV-negative patients and compares their characteristics with 10 HIV-associated cases of PEL diagnosed at a single institution in Italy between 1995 and 2019. METHODS Clinical records were reviewed for demographic data, comorbidities, laboratory abnormalities, and outcome. PEL samples were evaluated for cytomorphology, immunophenotype, immunoglobulin (IG)/T cell receptor (TR) rearrangements, and HHV8 and Epstein-Barr virus (EBV) viral loads in effusion supernatants. RESULTS HIV-unrelated PEL occurred in 8 elderly patients (7 men, 1 woman) and 1 young adult with primary antibody deficiency. Cytology revealed HHV8-positive lymphoma cells lacking B/T cell antigens and exhibiting 2 cell patterns (polymorphous or monotonous).IGwas clonally rearranged in all cases; aberrantTRGoccurred in 2 cases. Effusion supernatants had more than 10(6)HHV8 DNA copies per mL and variable loads of EBV DNA. Compared with HIV-associated PEL, the HIV-negative cohort was characterized by older age, less frequent association with Kaposi sarcoma and/or multicentric Castleman disease, comparable but less abnormal laboratory parameters, and a nonsignificant survival benefit. PEL cases with low apoptosis were associated with better prognosis. CONCLUSION To the best of our knowledge, our case series of HIV-unrelated PEL is the largest thus far, expands the spectrum of cytological findings, and supports the need for a multidisciplinary approach in the diagnostic workup.

The effects of beta(1)and beta(1+2)adrenergic receptor blockade on the exercise-induced mobilization and ex vivo expansion of virus-specific T cells: implications for cellular therapy and the anti-viral immune effects of exercise

CELL STRESS & CHAPERONES

Authors: Kunz, Hawley E.; Agha, Nadia H.; Hussain, Maryam; LaVoy, Emily C.; Smith, Kyle A.; Mylabathula, Preteesh; Diak, Douglass; Baker, Forrest L.; O'Connor, Daniel P.; Bond, Richard A.; Katsanis, Emmanuel; Bollard, Catherine M.; Simpson, Richard J.

The adoptive transfer of donor-derived virus-specific T cells (VSTs) is an effective treatment for infections following allogeneic hematopoietic cell transplantation. Acute exercise mobilizes effector lymphocytes and VSTs to the circulation and augments the ex vivo manufacture of VSTs. This study determined if beta(2)adrenergic receptor (AR) signaling precipitated the VST response to acute exercise. Healthy participants (n = 12) completed 30 min of steady-state cycling exercise after ingesting a placebo, a beta(1 + 2)AR antagonist (nadolol) or a beta(1)AR antagonist (bisoprolol). Circulating VSTs to cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (AdV) antigens were enumerated before and after exercise, and peripheral blood mononuclear cells were cultured with viral peptides for 8 days to expand multi-VSTs. Compared with placebo, nadolol blunted the exercise-induced mobilization of CMV-VSTs (Delta VSTs/100,000 CD3(+)T cells = 93 +/- 104 vs. 22 +/- 91 for placebo and nadolol, respectively;p = 0.036), while bisoprolol did not, despite both drugs evoking similar reductions in exercising heart rate and blood pressure. Circulating AdV and EBV VSTs (VSTs/mL blood) only increased after exercise with placebo. Although not significant, nadolol partially mitigated exercise-induced increases in multi-VST expansion, particularly in participants that demonstrated an exercise-induced increase in VST expansion. We conclude that exercise-induced enhancements in VST mobilization and expansion are at least partially beta(2)AR mediated, thus highlighting a role for the beta(2)AR in targeted therapy for the augmentation of VST immune cell therapeutics in the allogeneic adoptive transfer setting. Moreover, long-term regular exercise may provide additional viral protection in the host through frequent beta(2)AR-dependent mobilization and redistribution of VSTs cumulated with each bout of exercise.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket